^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

NFKB1 expression

i
Other names: NFKB1, KBF1, NF-kappaB, NF-kB1, NFkappaB, NFKB-p50, p105, p50, Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
Entrez ID:
Related biomarkers:
3d
Ruxolitinib improves the inflammatory microenvironment, restores glutamate homeostasis, and promotes functional recovery after spinal cord injury. (PubMed, Neural Regen Res)
Additionally, in glutamate-induced excitotoxicity astrocytes, ruxolitinib restored EAAT2 expression and increased glutamate uptake by inhibiting the activation of STAT3, thereby reducing glutamate-induced neurotoxicity, calcium influx, oxidative stress, and cell apoptosis, and increasing the complexity of dendritic branching. Collectively, these results indicate that ruxolitinib restores glutamate homeostasis by rescuing the expression of EAAT2 in astrocytes, reduces neurotoxicity, and effectively alleviates inflammatory and immune responses after spinal cord injury, thereby promoting functional recovery after spinal cord injury.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IL1B (Interleukin 1, beta)
|
NFKB1 expression
|
Jakafi (ruxolitinib)
6d
Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death. (PubMed, Cell Death Dis)
In primary leukemic cells, DMF disrupted the TLR signaling pathways induced by CpG by reducing the mRNA expression of NFKBIZ, IL6, IL10 and TNFα. Our data suggest that DMF targets a vulnerability of CLL cells linked to their inflammatory pathways, without impacting healthy donor peripheral blood mononuclear cells.
Journal • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
|
NFKB1 expression • IL6 expression
16d
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=30, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date • Combination therapy
|
MIR155 (MicroRNA 155) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1)
|
miR-155 expression • NFKB1 expression
|
decitabine • pevonedistat (MLN4924)
1m
The effects of cannabidiol against Methotrexate-induced lung damage. (PubMed, Basic Clin Pharmacol Toxicol)
Remarkably, CBD treatment reversed these findings. This study highlights CBD's potential in mitigating MTX-induced lung damage, suggesting its therapeutic promise.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • APAF1 (Apoptotic peptidase activating factor 1)
|
BCL2 expression • NFKB1 expression
|
methotrexate
1m
Trial completion
|
NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • FKBP5 (FKBP Prolyl Isomerase 5)
|
NFKB1 expression • FKBP5 expression
2ms
Hibiscetin attenuates lipopolysaccharide-evoked memory impairment by inhibiting BDNF/caspase-3/NF-κB pathway in rodents. (PubMed, PeerJ)
The results demonstrated that the hibiscetin-treated group exhibited significant recovery in LPS-induced memory deficits in rats by using behavioral paradigms, biochemical parameters, antioxidant levels, oxidative stress, neuroinflammatory markers, and apoptosis markers. Recent research suggested that hibiscetin may serve as a promising neuroprotective agent in experimental animals and could offer an alternative in LPS-injected memory deficits in rodent models.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta) • BDNF (Brain Derived Neurotrophic Factor) • CAT (Catalase)
|
NFKB1 expression • IL6 expression
2ms
A peptide encoded by the circular form of the SHPRH gene induces apoptosis in neuroblastoma cells. (PubMed, PeerJ)
The SHPRH-146aa-RUNX1 interaction further elucidates a novel pathway in the regulation of apoptosis in NB. These findings indicate that circ-SHPRH and its derived peptide SHPRH-146aa could be potential therapeutic targets for NB treatment.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • RUNX1 (RUNX Family Transcription Factor 1) • CASP3 (Caspase 3) • NFKBIA (NFKB Inhibitor Alpha 2) • SHPRH (SNF2 Histone Linker PHD RING Helicase)
|
NFKB1 expression
2ms
PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway. (PubMed, Cancer Biomark)
Our study confirms that PD-1 inhibitors in combination with Docetaxel are a viable combination strategy and provide a safe and effective combination option for the clinical treatment of prostate cancer.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CD4 (CD4 Molecule)
|
NFKB1 expression
|
docetaxel • AiRuiKa (camrelizumab)
2ms
Unraveling the therapeutic potential of ginsenoside compound Mc1 in Alzheimer's disease: Exploring the role of AMPK/SIRT1/NF-κB signaling pathway and mitochondrial function. (PubMed, Adv Clin Exp Med)
We showed that GCMc1 confers substantial neuroprotection in rats with AD by modulating the AMPK/SIRT1/NF-κB signaling pathway. These findings highlight the potential of GCMc1 as a promising therapeutic agent for AD treatment.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
|
NFKB1 expression • AMPK expression
3ms
Fe-Capsaicin Nanozymes Attenuate Sepsis-Induced Acute Lung Injury via NF-κB Signaling. (PubMed, Int J Nanomedicine)
The nanoparticles showed non-cytotoxicity, when studying these biological activities. Fe-CAP NPs could alleviated inflammation by inhibiting the expression of pro-inflammatory factors in macrophages, increasing the expression of anti-inflammatory factors, and alleviating lung tissue damage.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • TGFB1 (Transforming Growth Factor Beta 1)
|
NFKB1 expression • IL6 expression
3ms
Eucalyptol regulates Nrf2 and NF-kB signaling and alleviates gentamicin-induced kidney injury in rats by downregulating oxidative stress, oxidative DNA damage, inflammation, and apoptosis. (PubMed, Toxicol Mech Methods)
In addition, eucalyptol treatment ameliorated the histopathological changes that occurred with gentamicin. The results of our study show that eucalyptol has anti-inflammatory, antioxidative, antiapoptotic, nephroprotective, and curative effects on gentamicin-induced nephrotoxicity.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • IL1B (Interleukin 1, beta) • CAT (Catalase)
|
NFKB1 expression
3ms
Doxorubicin impairs cognitive function by upregulating AMPAR and NMDAR subunit expression and increasing neuroinflammation, oxidative stress, and apoptosis in the brain. (PubMed, Front Pharmacol)
GluA1, NR2B, and NR2A expression and MDA, NF-κB, Bax, COX-2, TNF-α, and caspase-3 levels in the brain were significantly elevated in DOX-treated rats. DOX induced cognitive impairment in the rats via neuronal toxicity by upregulating AMPAR and NMDAR expression and increasing neuroinflammation, oxidative stress, and apoptosis in the brain.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
|
BAX expression • NFKB1 expression • PTGS2 expression
|
doxorubicin hydrochloride
4ms
Comparative Transcriptome Analyses in Mantle Cell Lymphoma (MCL): Evidence of E2F1 As a Major Target in Aggressive Blastoid MCL Model (ASH 2023)
The mainstay of MCL therapies remains the chemo-immunotherapy followed by autologous transplantation but recently several novel therapies have been developed such as BTK inhibitors, Venetoclax, CDK4/6 inhibitors and more recently CAR-T therapies...Finally, the expression of PIK3CD which encodes for a therapeutic target in MCL (such as PI3KDelta inhibitor Idelalisib) was also significantly repressed in UPN-1 as compared to nine other MCL cell lines...This cell line exhibited a major upregulation of E2F1 expression and a down regulation of the cell cycle inhibitor CDKN1A(p21). The potential effects of the direct inhibition of E2F1 using the targeted inhibitor MTA demonstrated a reduction in cell proliferation and induction of apoptosis, suggesting the possibility of associating clinically acceptable E2F1 inhibition strategies to other current therapies.
BRCA Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • RAD51 (RAD51 Homolog A) • CDK2 (Cyclin-dependent kinase 2) • CCNB2 (Cyclin B2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • NFKBIA (NFKB Inhibitor Alpha 2) • E2F1 (E2F transcription factor 1)
|
TP53 mutation • PIK3CD expression • NFKB1 expression
|
Venclexta (venetoclax) • Zydelig (idelalisib)
4ms
Regulation of NF-κB Expression by Thymoquinone; A Role in Regulating Pro-Inflammatory Cytokines and Programmed Cell Death in Hepatic Cancer Cells. (PubMed, Asian Pac J Cancer Prev)
These results indicate that TQ mediates the activation of Casp3, DLC1, and NF-κB, providing a new function of TQ in treating hepatocellular carcinoma (HCC).
Journal
|
NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • CASP3 (Caspase 3)
|
NFKB1 expression
4ms
Validation of SSTR2 Expression and Assessing Correlation of Variable F18-FDG PET/CT Parameters in EBV Associated Nasopharyngeal Cancer (RSNA 2023)
EBV associated NPC showed stronger expression of SSTR2 comparing to HNSCC in other subsites. No significant difference in F18-FDG PET/CT parameters between EBV positive NPC and other types of HNSCC. Future directions would include assessing the role of Cu 64 -DOTATATE PET/MRI in evaluation of EBV positive NPC and its impact on radiation therapy planning.
FDG PET
|
SSTR (Somatostatin Receptor) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • SSTR2 (Somatostatin Receptor 2)
|
NFKB1 expression • SSTR2 expression
4ms
RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial. (PubMed, Clin Cancer Res)
We report RANK expression to be an independent predictive biomarker for response to NACT in luminal-like breast cancer patients.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • TNFRSF11A (TNF Receptor Superfamily Member 11a) • TNFSF11 (TNF Superfamily Member 11)
|
NFKB1 expression
|
albumin-bound paclitaxel • Prolia (denosumab)
5ms
Tumor Inflammatory Microenvironment of the Thyroid Cancer: Relationship between Regulatory T-Cell Imbalance, and p-NFΚB (p65) Expression-A Preliminary Study. (PubMed, J Clin Med)
Strong inflammatory infiltrate in the tumor microenvironment is correlated with an invasive phenotype. CD25 and p-NFkB levels were statistically significantly overexpressed in cancer cells.
Journal
|
IL2RA (Interleukin 2 receptor, alpha) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • ISG20 (Interferon Stimulated Exonuclease Gene 20) • RELA (RELA Proto-Oncogene)
|
IL2RA expression • NFKB1 expression • RELA expression
5ms
Friedelin and Glutinol induce neuroprotection against ethanol induced neurotoxicity in pup's brain through reduction of TNF-α, NF-kB, Caspase-3 and PARP-1. (PubMed, Neurotoxicology)
This protection may be attributed to the revival of p-Akt signaling for cell survival. It is concluded that the present study demonstrates the neuro-protective effects of friedelin and glutinol via modulating the capase-3 and PARP-1 expression and modulating the neuronal apoptotic pathways.
Journal • PARP Biomarker
|
TNFA (Tumor Necrosis Factor-Alpha) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • CASP3 (Caspase 3)
|
NFKB1 expression • PARP1 expression • PARP1 overexpression • TNFA overexpression
5ms
Nuclear factor kappa B expression in non-small cell lung cancer. (PubMed, Biomed Pharmacother)
In response to oxidants, S-glutathionylation of NF-κB also correlated with enhanced lung inflammation. Thus, S-glutathionylation is an important contributor to NF-κB regulation and clinical results highlight the importance of NF-κB in NSCLC, where NF-κB levels are associated with unfavorable prognosis.
Journal
|
NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1)
|
NFKB1 expression
5ms
Drug metabolism and inflammation related distinct miRNA signature of colchicine resistant familial Mediterranean fever patients. (PubMed, Int Immunopharmacol)
This is the first study evaluating the role of miRNAs in colchicine resistant patients with FMF. Their differential expression may result in resistance to standard colchicine treatment by affecting the expression of genes that take place in drug absorption, distribution, metabolism, and excretion (ADME) or nuclear receptors that regulate ADME genes, thus potentially playing a role in both drug metabolism and inflammation.
Journal
|
MIR125A (MicroRNA 125a) • MIR15B (MicroRNA 15b) • MIR183 (MicroRNA 183) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
|
NFKB1 expression
5ms
Aerobic Exercise Ameliorates Liver Injury in Db/Db Mice by Attenuating Oxidative Stress, Apoptosis and Inflammation Through the Nrf2 and JAK2/STAT3 Signalling Pathways. (PubMed, J Inflamm Res)
Additionally, exercise significantly increased SOD activity, decreased MDA levels, activated Nrf2 and decreased the expression of NF-kB, phosphorylated JAK2 and STAT3 proteins in the livers of diabetic mice. This study demonstrated that aerobic exercise reversed liver dysfunction in db/db mice with T2DM by reducing oxidative stress, apoptosis and inflammation, possibly by enhancing Nrf2 expression and inhibiting the JAK2/STAT3 cascade response.
Preclinical • Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • CASP3 (Caspase 3)
|
NFKB1 expression
5ms
The Expression and Activation of the NF-κB Pathway Correlate with Methotrexate Resistance and Cell Proliferation in Acute Lymphoblastic Leukemia. (PubMed, Genes (Basel))
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. At the individual gene level, NFKB1 expression was directly associated with a poorer clinical response to MTX and with both an increased TNF-α-triggered NF-κB activation and MTX resistance in the cell lines. Despite these results, the pharmacological inhibition (using BAY 11-7082 and parthenolide) or stimulation (using exogenous TNF-α supplementation) of the NF-κB pathway did not alter the MTX resistance of the cell lines significantly, evidencing a complex interplay between MTX and NF-κB in ALL.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha)
|
NFKB1 expression
|
methotrexate • Bay11-7082
5ms
Pancreatic neuroendocrine tumor progression and resistance to everolimus: the crucial role of NF-kB and STAT3 interplay. (PubMed, J Endocrinol Invest)
Since the NF-kB pathway is implicated in Pa-NETs' progression and resistance to everolimus, these data could explain the potential use of NF-kB as a novel therapeutic target in Pa-NET patients.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • STAT3 (Signal Transducer And Activator Of Transcription 3) • SOCS3 (Suppressor Of Cytokine Signaling 3)
|
NFKB1 expression • CXCL8 expression
|
everolimus
6ms
TFAM Modulates Cardiomyocytes Pyroptosis Induced by Ionizing Radiation through mtDNA/TLR9/NF-kB Pathway. (PubMed, Int J Radiat Oncol Biol Phys)
Our study indicated that TFAM regulate irradiated cardiomyocytes pyroptosis through mtDNA/TLR9/NF-kB pathway. We provide a novel mechanism of RIMD, revealing an underappreciated intervention target for RIMD.
Journal
|
IL18 (Interleukin 18) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • TFAM (Transcription Factor A, Mitochondrial)
|
TLR9 expression • NFKB1 expression
6ms
Murine leukemia virus (MLV) P50 protein induces cell transformation via transcriptional regulatory function. (PubMed, Retrovirology)
We propose a novel SDARE-mediated mode of propagation of the P50 accessory protein in surrounding cells. Moreover, due to its transforming properties, P50 expression could lead to a cellular and tissue microenvironment that is conducive to cancer development.
Preclinical • Journal
|
NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1)
|
NFKB1 expression
7ms
TP53 Induced Glycolysis and Apoptosis Regulator and Monocarboxylate Transporter 4 drive metabolic reprogramming with c-MYC and NFkB activation in breast cancer. (PubMed, Int J Cancer)
Metabolic coupling primes the tumor microenvironment allowing for production, uptake and utilization of lactate. In sum, aggressive breast cancer is dependent on metabolic coupling.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IL6 (Interleukin 6) • CAV1 (Caveolin 1) • TIGAR (TP53 Induced Glycolysis Regulatory Phosphatase)
|
NFKB1 expression
7ms
Withania somnifera extract reduces gastric cancerous properties through inhibition of gankyrin in cellular milieu produced by Helicobacter pylori and Epstein Barr virus. (PubMed, J Biomol Struct Dyn)
Moreover, molecular simulation studies revealed that out of eight active compounds of WSE, only four compounds such as withaferin A (WFA), withanoside IV (WA4), withanolide B (WNB), and withanolide D (WND) showed direct stable interaction with Gankyrin. This article reports for the first time that treatment of WSE decreased the cancerous properties through host cellular response modulation in gastric epithelial cells coinfected with H. pylori and EBV.Communicated by Ramaswamy H. Sarma.
Journal • PARP Biomarker • IO biomarker
|
PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • PCNA (Proliferating cell nuclear antigen) • APAF1 (Apoptotic peptidase activating factor 1) • MMP3 (Matrix metallopeptidase 3) • MMP7 (Matrix metallopeptidase 7)
|
BAX expression • NFKB1 expression
7ms
NF-ĸΒ1 knockout reduces IL6 expression under hypoxia in renal cell carcinoma. (PubMed, Cell Mol Biol (Noisy-le-grand))
Suppression of p50 expression in 786-0 single guide RNA (sg)1, 786-0 sg2 and 786-0 sg3 cells downregulated IL-6 mRNA and protein expression under normoxia and hypoxia. The observed decrease in the differential expression of IL-6 in hypoxia/normoxia is suggestive of a change in cellular responsiveness to hypoxia with respect to IL-6.
Journal
|
IL6 (Interleukin 6) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1)
|
VHL mutation • NFKB1 expression • IL6 expression
7ms
Correlation of Before and After Invasive Breast Cancer Neoadjuvant Chemotherapy for NFkB, Cyclin D1, and Survivin Expression. (PubMed, Iran J Pathol)
The high potential of these proteins as prognostic indicators was demonstrated by the strong positive association between the expression of Survivin and Cyclin D1 before and after the NC. This upregulation of biomarkers indicates chemoresistance in developing IBC in the presence of NC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CCND1 (Cyclin D1) • BIRC5 (Baculoviral IAP repeat containing 5) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1)
|
CCND1 expression • BIRC5 expression • NFKB1 expression
7ms
MiR-196b-5p activates NF-κB signaling in non-small cell lung cancer by directly targeting NFKBIA. (PubMed, Transl Oncol)
Our findings indicated that the miR-224/QKI-5/miR-196b-5p/NFKBIA signaling pathway might play important functions in the progression of NSCLC, and suggested that targeting this pathway might be an effective therapeutic strategy in treating NSCLC.
Journal
|
IL6 (Interleukin 6) • STAT3 (Signal Transducer And Activator Of Transcription 3) • GATA6 (GATA Binding Protein 6) • QKI (QKI, KH Domain Containing RNA Binding) • NFKBIA (NFKB Inhibitor Alpha 2) • MIR196B (MicroRNA 196b) • MIR224 (MicroRNA 224)
|
NFKB1 expression
8ms
Effects of the Co-Administration of Morphine and Lipopolysaccharide on Toll-Like Receptor-4/Nuclear Factor Kappa β Signaling Pathway of MDA-MB-231 Breast Cancer Cells. (PubMed, Adv Biomed Res)
However, no significant change was observed in interleukin 2 beta concentration. These findings confirmed the excitatory effects of morphine on TRL4 expression and the MYD88 signaling pathway in vitro.
Journal • IO biomarker
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IL2 (Interleukin 2) • TLR4 (Toll Like Receptor 4)
|
NFKB1 expression
8ms
SGLT2 i dapagliflozin reduces NF-kB expression in heart and kidneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways (ESMO 2023)
Radial strain (RS) is 38.8% in DAPA-DOXO vs 14.1% in DOXO groups (P < 0.05); longitudinal strain (LS) is – 23.4 % in DAPA-DOXO vs – 10.5% in DOXO groups (P < 0.001) Conclusions In this preclinical study, DAPA is able to improve cardiac function and reduce biomarkers involved in heart failure and fibrosis. The overall picture of the study pushes the use of DAPA in prevention of cardiomyopathies induced by anthracyclines in cancer patients.
Preclinical
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • CSF2 (Colony stimulating factor 2) • IL18 (Interleukin 18) • IL17A (Interleukin 17A) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • NLRP3 (NLR Family Pyrin Domain Containing 3)
|
NFKB1 expression • IL6 expression
|
doxorubicin hydrochloride • Farxiga (dapagliflozin)
8ms
Single cell transcriptomics of the immune cells during chemotherapy in triple-negative breast cancer patients (ESMO 2023)
DUSP4, LCK, CXCR4, LTB, TNFRSF18, IL2RB and PTPN7 genes were overexpressed and involved in the regulation of cytokine secretion and inhibition of TCR signaling in CD4+ and CD8+ T cells; chemotaxis-mediated inflammation in memory B cells; T cells differentiation, and induction of invasion/migration of tumor cells in T-regulatory cells and plasma cells. Conclusions The first cycle of NACT induced renewal of the immune cells' composition in the blood and tumor microenvironment skewing towards to immune disfunction.
Clinical • IO biomarker • Immune cell
|
HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • CD4 (CD4 Molecule) • ANXA1 (Annexin A1) • TNFRSF18 (TNF Receptor Superfamily Member 18) • NFKBIA (NFKB Inhibitor Alpha 2) • DUSP4 (Dual Specificity Phosphatase 4) • JUN (Jun proto-oncogene) • MX1 (MX Dynamin Like GTPase 1) • RGS2 (Regulator Of G Protein Signaling 2)
|
NFKB1 expression
9ms
Independent validation of somatostatin receptor 2 as a sensitive and specific biomarker for Epstein-Barr virus status in sinonasal/nasopharyngeal squamous cell carcinoma (ECP 2023)
The median H-score for EBVNPC was 180 (range 12-295; mean 179), whereas the median H-scores for HPVSCC and VNSCC were 0 (range 0-56; mean 8) and 0 (range 0-125; mean 31), respectively (p<0.001 for EBVNPC compared to either). Conclusion Our study validates the strong correlation between SSTR2 immunohistochemistry and EBV status in NPCs, supports its use in clinical practice as a highly sensitive and specific surrogate biomarker, and lends credence to exploring SSTR2-targeted imaging and therapy.
SSTR (Somatostatin Receptor) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • SSTR2 (Somatostatin Receptor 2)
|
NFKB1 expression • SSTR2 expression
9ms
Clinical relevance of molecular aspects in extranodal marginal zone lymphoma: a critical appraisal. (PubMed, Ther Adv Med Oncol)
While small series have shown no influence on the outcome for treatment with the anti-CD20 antibody rituximab (R) or treatment with cladribine (2-CdA), conflicting data have been reported for alkylating agents, especially chlorambucil and the combination of R + chlorambucil. None of other genetic changes seen in MALT lymphoma to date has discernible value in routine clinical applications, but recent data suggest that changes in TNFAIP3(A20), KMTD2 and CARD11 might be associated with response to Bruton kinase inhibitors.
Review • Journal
|
BIRC3 (Baculoviral IAP repeat containing 3) • CARD11 (Caspase Recruitment Domain Family Member 11) • TNFAIP3 (TNF Alpha Induced Protein 3) • MALT1 (MALT1 Paracaspase)
|
NFKB1 expression
|
Rituxan (rituximab) • cladribine • Leukeran (chlorambucil)